AA
SCLN

AlphaMark Advisors’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

AlphaMark Advisors’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-76
Closed -$1K – 481
2016
Q3 		$1K Hold
76
– – ﹤0.01% 337
2016
Q2 		$1K Buy
+76
New +$996 ﹤0.01% 329

Other funds holding SCLN

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

AlphaMark Advisors's SCLN Position: Q4 2016 in Review

AlphaMark Advisors sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2016, closing a stake of 76 shares — an estimated $1K sold.

AlphaMark Advisors first reported a position in SCLN in Q2 2016 and held it in 2 quarters. The position peaked at $1K in Q3 2016. 153 funds tracked by Wall St. Rank hold SCLN as of Q4 2016.

  • AlphaMark Advisors reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2016 after selling out during the quarter.
  • AlphaMark Advisors sold 76 Sciclone Pharmaceuticals Inc shares in Q4 2016, an estimated $1K.
  • AlphaMark Advisors first reported a position in Sciclone Pharmaceuticals Inc in Q2 2016 and held it in 2 quarters.
  • AlphaMark Advisors's Sciclone Pharmaceuticals Inc position peaked at $1K in Q3 2016.
  • 153 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2016.

Based on AlphaMark Advisors's 13F filing for Q4 2016, filed 26 Jan 2017.